您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
PCSK9 Recombinant Rabbit mAb (SDT-424-252)

PCSK9 Recombinant Rabbit mAb (SDT-424-252)

货号: S0B3245
价格: 5000
规格: 1mg
介绍: -
其他: -
产品规格
  • 宿主来源

    Rabbit
  • 分子别名

    Neural apoptosis-regulated convertase 1 (NARC-1); Proprotein convertase 9 (PC9); Subtilisin/kexin-like protease PC9
  • 免疫原

    Recombinant Protein
  • Accession

    Q8NBP7
  • 克隆号

    SDT-424-252
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 应用

    Sandwich ELISA
  • 反应种属 ?

    Hu
  • 交叉反应

    Does not recognize CHI3L1
  • 纯化方式

    Protein A
  • 浓度

    2 mg/ml
  • 纯度

    >95% by HPLC
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    Na-citrate, pH 6.0, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt, 2 to 8 °C as supplied

稀释度
应用 稀释度
Sandwich ELISA N/A
背景介绍
  • PCSK9 is ubiquitously expressed in many tissues and cell types. PCSK9 binds to and degrades the receptor for low-density lipoprotein particles (LDL), which typically transport 3,000 to 6,000 fat molecules (including cholesterol) per particle, within extracellular fluid. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells and targets the complex to lysosomes for destruction. If PCSK9 is blocked, the LDL-LDLR complex separates during trafficking, with the LDL digested in the lysosome, but the LDLRs instead recycled back to the cell surface and so able to remove additional LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations. PCSK9 has medical importance because it acts in lipoprotein homeostasis. Agents that block PCSK9 can lower LDL particle concentrations. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated. PCSK9 inhibitors are promising therapeutics for the treatment of people who exhibit statin intolerance, or as a way to bypass frequent dosage of statins for higher LDL concentration reduction. So, measurement of plasma PCSK9 level will be more useful for monitoring treatment effect.

  • 配对推荐